Aki Nishioka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Aki Nishioka has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Hajime Sano
Division of Diabetes, Endocrinology and Clinical Immunology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan
2 shared publicationsKiyoshi Matsui
Division of Diabetes, Endocrinology and Clinical Immunology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan
2 shared publicationsMasayasu Kitano
Division of Diabetes, Endocrinology and Clinical Immunology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan
2 shared publicationsTakahiro Yoshikawa
Division of Diabetes, Endocrinology and Clinical Immunology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan
2 shared publications- Koichiro Ohmura
Department of Rheumatology, Kobe City Medical Center General Hospital , Kobe
1 shared publication Masahiro Sekiguchi
Division of Diabetes, Endocrinology and Clinical Immunology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan
1 shared publication
Latest Publications
- 30 July 2020
- Published by Oxford University Press (OUP) in Modern Rheumatology
- Vol. 31 (3) , 669-677
Evaluation of changes in oral health-related quality of life over time in patients with Sjögren’s syndrome
Objectives: To assess oral health-related quality of life (OHRQoL) and changes in OHRQoL in three years of patients with Sjögren’s symdrome (SS). Methods: Thirty-five SS patients and 23 non-SS individuals were enrolled. OHRQoL were quantitatively evaluated using the shortened Oral Health Impact Profile (OHIP-14). After three years, 22 patients and 14 controls tool the OHIP-14 survey again. Results: The SS group had a significantly higher OHIP-14 score, which indicated a lower OHRQoL, than the non-SS group. Among individual questions in the OHIP-14, scores for “trouble pronouncing words”, “uncomfortable to eat foods”, “self-conscious”, and “diet unsatisfactory” were markedly higher in the SS group than in the non-SS group. The OHIP-14 score significantly increased in three years in the SS group. Furthermore, there was an inverse correlation between the change rate of salivary flow rate and change of OHIP-14 scores in three years in patients with SS whose OHIP-14 score increased. Scores for “irritable with other people”, “difficulty doing usual jobs”, “felt life less satisfying”, and “unable to function” significantly increased in three years. Conclusions: In SS, OHRQoL decreased in three years, which was associated with a decrease in saliva secretion. Moreover, troubles related to psychosocial aspects in SS patients were found to intensify over time.
- 30 July 2020
- Published by Oxford University Press (OUP) in Modern Rheumatology
- Vol. 31 (3) , 669-677
Evaluation of changes in oral health-related quality of life over time in patients with Sjögren’s syndrome
Objectives: To assess oral health-related quality of life (OHRQoL) and changes in OHRQoL in three years of patients with Sjögren’s symdrome (SS). Methods: Thirty-five SS patients and 23 non-SS individuals were enrolled. OHRQoL were quantitatively evaluated using the shortened Oral Health Impact Profile (OHIP-14). After three years, 22 patients and 14 controls tool the OHIP-14 survey again. Results: The SS group had a significantly higher OHIP-14 score, which indicated a lower OHRQoL, than the non-SS group. Among individual questions in the OHIP-14, scores for “trouble pronouncing words”, “uncomfortable to eat foods”, “self-conscious”, and “diet unsatisfactory” were markedly higher in the SS group than in the non-SS group. The OHIP-14 score significantly increased in three years in the SS group. Furthermore, there was an inverse correlation between the change rate of salivary flow rate and change of OHIP-14 scores in three years in patients with SS whose OHIP-14 score increased. Scores for “irritable with other people”, “difficulty doing usual jobs”, “felt life less satisfying”, and “unable to function” significantly increased in three years. Conclusions: In SS, OHRQoL decreased in three years, which was associated with a decrease in saliva secretion. Moreover, troubles related to psychosocial aspects in SS patients were found to intensify over time.
- 7 February 2019
- Published by Oxford University Press (OUP) in Modern Rheumatology
- Vol. 29 (5) , 814-820
Serum neopterin as well as ferritin, soluble interleukin-2 receptor, KL-6 and anti-MDA5 antibody titer provide markers of the response to therapy in patients with interstitial lung disease complicating anti-MDA5 antibody-positive dermatomyositis
Objective: This study identified biomarkers that can be used to assess disease activity and response to therapy in patients with interstitial lung disease complicating anti-melanoma differentiation-associated gene 5 (MDA5) antibody (Ab)-positive clinically amyopathic dermatomyositis (CADM). Methods: In 15 patients with interstitial lung disease complicating anti-MDA5 Ab-positive CADM, anti-MDA5 Ab, neopterin, interleukin (IL)-18, ferritin, and soluble interleukin 2 receptor (sIL-2R) levels were measured in cryopreserved serum specimens before and at multiple times after remission induction therapy, and their correlations were assessed. Results: Anti-MDA5 Ab, neopterin, IL-18, ferritin, and sIL-2R levels did not differ significantly between patients who survived and those who succumbed to the disease. In many cases, serum anti-MDA5 Ab titers were over the upper limit (over 150 index value) before treatment in the usual measuring method, and gradually decreased to the normal range at stable phase. Meanwhile, serum neopterin levels (21.6 [15.3-48.3] nmol/L) were significantly elevated in newly diagnosed patients and fell to 6.8 (5-11.4) nmol/L at 6 months after treatment introduction. Conclusions: Elevated serum neopterin as well as ferritin, sIL-2R, KL-6, and anti-MDA5 Ab titer might help identify patients with interstitial lung disease complicated with DM and might be useful in monitoring response to therapy.
- 7 February 2019
- Published by Oxford University Press (OUP) in Modern Rheumatology
- Vol. 29 (5) , 814-820
Serum neopterin as well as ferritin, soluble interleukin-2 receptor, KL-6 and anti-MDA5 antibody titer provide markers of the response to therapy in patients with interstitial lung disease complicating anti-MDA5 antibody-positive dermatomyositis
Objective: This study identified biomarkers that can be used to assess disease activity and response to therapy in patients with interstitial lung disease complicating anti-melanoma differentiation-associated gene 5 (MDA5) antibody (Ab)-positive clinically amyopathic dermatomyositis (CADM). Methods: In 15 patients with interstitial lung disease complicating anti-MDA5 Ab-positive CADM, anti-MDA5 Ab, neopterin, interleukin (IL)-18, ferritin, and soluble interleukin 2 receptor (sIL-2R) levels were measured in cryopreserved serum specimens before and at multiple times after remission induction therapy, and their correlations were assessed. Results: Anti-MDA5 Ab, neopterin, IL-18, ferritin, and sIL-2R levels did not differ significantly between patients who survived and those who succumbed to the disease. In many cases, serum anti-MDA5 Ab titers were over the upper limit (over 150 index value) before treatment in the usual measuring method, and gradually decreased to the normal range at stable phase. Meanwhile, serum neopterin levels (21.6 [15.3-48.3] nmol/L) were significantly elevated in newly diagnosed patients and fell to 6.8 (5-11.4) nmol/L at 6 months after treatment introduction. Conclusions: Elevated serum neopterin as well as ferritin, sIL-2R, KL-6, and anti-MDA5 Ab titer might help identify patients with interstitial lung disease complicated with DM and might be useful in monitoring response to therapy.